The global proteomics market was valued at USD 24.29 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 13.10% from 2024 to 2030. Several key factors are contributing to this significant growth, including the increasing prevalence of chronic and infectious diseases, the rising demand for rapid and advanced diagnostic solutions for targeted disease treatment, and the growing emphasis on personalized medicine. Additionally, ongoing technological advancements in protein analysis and proteomic tools are further propelling the expansion of the market.
One of the primary drivers of the proteomics market is the increasing occurrence of chronic and infectious diseases worldwide. For instance, the World Health Organization (WHO) has projected that by 2050, there will be over 35 million new cases of cancer annually, a sharp rise of 77% compared to the 20 million cases estimated in 2022. This rising incidence of chronic diseases, including cancer, diabetes, and cardiovascular conditions, is spurring the need for advanced diagnostics, therapeutic development, and research into disease pathogenesis. Proteomics plays a vital role in these areas by helping to identify the underlying mechanisms of diseases at the molecular level, leading to the development of more effective and precise diagnostic tools and therapies.
Gather more insights about the market drivers, restrains and growth of the Proteomics Market
As an example of proteomics' growing impact on disease research, a study published in Nature Communications in July 2024 highlighted the use of proteomics to investigate the interaction between host cells and pathogens. In this study, scientists employed a proteomics-based approach to identify proteins secreted by the Rickettsia species, deepening the understanding of the host-pathogen interface. Such insights could pave the way for new treatments and preventive strategies against infectious diseases.
Product Service Insights
In 2023, the reagents and consumables segment dominated the proteomics market, accounting for the largest revenue share at 72.29%. This segment encompasses a range of products, including kits for mass spectrometry, which allow researchers to accurately identify proteins within complex biological samples. These kits are essential for quantifying protein levels, which is critical for understanding cellular functions, disease mechanisms, and the identification of potential therapeutic targets. Reagents used in proteomic assays also play a crucial role in identifying novel biomarkers, particularly for early detection of diseases such as cancer, Alzheimer’s, and cardiovascular diseases. The discovery of these biomarkers facilitates the development of targeted therapies, a rapidly growing field in modern medicine.
The services segment of the proteomics market is expected to grow at the fastest CAGR from 2024 to 2030. This rapid expansion is attributed to the increasing demand for specialized expertise and advanced technologies in protein analysis. As proteomics research becomes more complex, organizations and research institutions are increasingly outsourcing specific tasks, such as mass spectrometry, protein identification, and data analysis, to specialized service providers. Companies like Charles River Laboratories, Cell Signaling Technology, and Creative Proteomics are at the forefront of offering these services, providing access to cutting-edge technology, comprehensive data interpretation, and cost-effective solutions. Outsourcing allows research teams to focus on their core activities while benefiting from expert support in complex proteomic tasks.
The growing adoption of personalized medicine is another key factor driving the demand for proteomic services. Personalized medicine aims to tailor treatments to individual patients based on their unique molecular profiles, often identified through proteomic analysis. Biomarker discovery, a critical component of personalized medicine, relies heavily on proteomics to identify disease-specific proteins that can serve as diagnostic markers or therapeutic targets. The increasing focus on this field is fueling the need for high-quality proteomic services, further accelerating the growth of this segment.
In conclusion, the proteomics market is poised for robust growth over the coming years, driven by technological innovations, the rising demand for personalized medicine, and the increasing prevalence of chronic and infectious diseases. Both the reagents consumables and services segments are expected to play a significant role in shaping the future of the industry, with advancements in protein analysis continuing to open new avenues for research, diagnostics, and therapeutic development.
Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.
